Solvanix Overview

  • Founded
  • 2014

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $1.63M

  • Investors
  • 1

Solvanix General Information


Developer of a novel technology designed to improve stability and reduce the aggregation of fully human antibodies. The company's technology helps to boost stability and reduce aggregation of monoclonal antibodies, antibody fragments, and bi-specifics, enabling biotech and pharma partners to improve therapeutic antibodies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Primary Office
  • 384 Victoria Street
  • Darlinghurst, New South Wales 2010
  • Australia
+61 0000000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Solvanix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 15-Jan-2015 $1.63M 00.000 Completed Generating Revenue
To view Solvanix’s complete valuation and funding history, request access »

Solvanix Executive Team (2)

Name Title Board Seat Contact Info
Daniel Christ Ph.D Founder & Chief Scientific Officer
Philip Wallace Ph.D Head of Product and Business Development
To view Solvanix’s complete executive team members history, request access »

Solvanix Board Members (2)

Name Representing Role Since
Christopher Smith Ph.D Brandon Capital Board Member 000 0000
Jenny Harry Ph.D Self Board Member 000 0000
To view Solvanix’s complete board members history, request access »

Solvanix Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brandon Capital Venture Capital Minority 000 0000 000000 0
To view Solvanix’s complete investors history, request access »